Pharmaceutical company Chiesi Group to acquire KalVista

The maker of recently licensed HAE medicine, sebetralstat (Ekterly), is to be acquired by Chiesi Group, an Italian-based pharmaceutical company seeking to build on their expertise in treating rare diseases.

The companies hope that this acquisition will combine KalVista’s innovation with Chiesi’s global rare disease capabilities, to accelerate patient access and strengthen medical and scientific engagement. The purchase is KalVista is expected to be finalized by Q3 2026.

Giacomo Chiesi, Executive Vice President, Chiesi Global Rare Diseases said: “This acquisition reflects our commitment to people living with rare conditions. In HAE, patients continue to face significant unmet needs, and KalVista’s innovation meaningfully expands our presence in rare immunology by adding a differentiated, on-demand treatment option that can bring meaningful advancement in how the disease can be managed. Our focus will be on working closely with the HAE community and the scientific community to improve disease management and ensure more patients can benefit from timely, effective treatment.”

Ben Palleiko, CEO of KalVista said: “I am extremely proud of what KalVista has accomplished over the past decade in advancing therapies for the unmet needs of people living with rare disease. With Chiesi’s global infrastructure, commercial capabilities and long-term commitment to rare diseases, we are confident in their ability to help expand access to sebetralstat for people living with HAE around the world.”

(Source: KalVista)